Binge eating · Patient experience
Binge eating's only drug is a morning pill for a nighttime disease
Patients named the problem years ago, in their own reviews, while the experts argued about something else. Now, as Ozempic promises to quiet the same hunger, we are about to repeat the mistake.
Based on
Armanious, A. J., Asare, A., Mitchison, D., & James, M. H. (2024). Patient perceptions of lisdexamfetamine as a treatment for binge eating disorder: An exploratory qualitative and quantitative analysis. Psychiatry Research Communications, 4(4), 100195. https://doi.org/10.1016/j.psycom.2024.100195
A mixed-methods study of ninety self-selected online reviews of Vyvanse for binge eating disorder, hand-coded and matched to each rating where they left one.
Disclosures: The lab I work in develops experimental compounds for compulsive eating, and my mentor holds a related patent on methods for reducing such behavior (PCT/US23/27918), though I do not. Separately, this piece explains research, not medical advice; any decision about a medication is one for you and your clinician.
Last November, a team at the University of Pennsylvania placed an electrode deep in the brain of a woman taking tirzepatide, one of the new GLP-1 drugs, and watched the signal for what people now call "food noise", the constant pull toward food, go quiet. At her highest dose, it fell silent. Then, around the fifth month, it came back, and her preoccupation with food came back with it, even though she had not stopped taking the drug.
It is a single patient, one recording inside a small early study, and what returned was the brain signal, not a documented relapse into bingeing. But it is a precise little warning about the question we keep forgetting to ask of any drug that quiets hunger. Not whether it works. But at what hour, and for how long.
A woman taking a different drug answered that second question years ago, for free, in an online review. She gave Vyvanse a 7 out of 10 and explained the missing points in a sentence:
It's a catch 22 because my binging happens at night. Taking the meds at night keeps me up.
A patient's review on Drugs.com.
She had just named a flaw the drug's own design built in, one its trials never thought to test for.
Vyvanse was not built for binge eating. It was built for ADHD. Its maker engineered it as the first amphetamine prodrug, inert until the body breaks it down, which gave it a longer, steadier day and less of the rush that makes a stimulant easy to abuse. The FDA approved it for ADHD in 2007, for children who had to sit through school, and the label was plain. Take it in the morning, never the afternoon, or it will keep you up at night. Not until 2015, after trials that showed it cut how often adults binged, did it become the only drug the FDA has ever approved for binge eating disorder. The morning schedule carried over unchanged. No one had stopped to ask when binge eating actually happens.
I work in pharmacoepidemiology. The part I focus on is what a drug does once it leaves the trial and enters real-world use. I read the reviews people wrote about taking Vyvanse for binge eating and coded them by hand. Eighty-nine of them had a rating from 1 to 10. Most were grateful. The single most common rating was a perfect 10. People wrote about the noise in their heads going quiet, about sitting through a meal without the pull to keep eating, the same relief the Ozempic coverage now describes as though it were new.
So I looked closely at the ones who rated it low, expecting the usual story. A stimulant is a hard drug to live on, and the side effects drive people off. That story was wrong. The physical side effects, the racing heart and the dry mouth, turned up about as often among the people who loved the drug as among the people who hated it, 26 percent against 28 percent, statistically indistinguishable. The side effects were real. They just decided nothing.
of the ninety I read left a rating from 1 to 10. Most of them piled up at the top, thirty-seven on a 10 and sixteen on a 9.
If you have taken it, where would you put it? See what others have said.
| Rating | Reviewers |
|---|---|
| 1 (lowest) | 5 |
| 2 | 2 |
| 3 | 5 |
| 4 | 1 |
| 5 | 4 |
| 6 | 1 |
| 7 | 10 |
| 8 | 8 |
| 9 | 16 |
| 10 (highest) | 37 |
| Total | 89 |
What set the low ratings apart was whether the drug kept working, and when. The most common complaint among the unhappy reviewers was tolerance, the sense that it did less every month. It appeared in 44 percent of low-rated reviews and 6 percent of high-rated ones. And underneath the tolerance was the clock. A morning dose is meant to carry someone through the workday, not the hours a binge keeps. The best clock-time data we have puts the peak of binge episodes around dinnertime, with a second spike near eleven at night, by which point the morning dose is fading or long gone.
No published work connects those two facts, so let me be plain. The next step here is my own reading, not settled science. A morning-dosed drug aimed at a nighttime disease is built on a mismatch, and the patients have been living inside it. Their reviews say as much. Some described the bingeing returning in the evening as the dose wore off. Others tried taking it later to cover the night and then could not sleep, the exact catch-22 the reviewer named. The one "side effect" that did track with low ratings was insomnia, and it was not really a side effect. It was people fighting the clock and losing.
Some of that night hunger is its own disorder, night eating syndrome, which shadows binge eating in a large share of patients, and no review can prove that a fading dose causes any single binge. But the overlap only sharpens the point. Whatever drives the night eating, the only approved drug has clocked out before the worst of it begins.
For a while, the public conversation about Vyvanse was loud, and it was about none of this. Its maker, the New York Times reported, had marketed the disease as energetically as the pill, and the argument that followed was over whether a stimulant with a history of abuse belonged anywhere near an eating disorder. That fight was about whether the drug should exist. Ten years on, the live problem is not whether but when, and the people who found it were not the critics or the company. They were the patients.
Now the same hunger has a fashionable new answer, and the same blind spot. "Food noise" entered the language through Ozempic, not through the disorder Vyvanse treats. A small chart review has already been read as semaglutide beating Vyvanse, though it was retrospective, not a head-to-head trial, and semaglutide is not approved for any eating disorder. And Scientific American ran a long feature on how Ozempic quiets food noise in the brain without once mentioning that there is a drug approved for precisely that, with a decade of patients who can tell you how it goes.
It goes like the electrode. That is the unsettling rhyme in the Penn result. The trendy drug may fail the way the old one does, the quiet lifting after a few months, the preoccupation creeping back. As Kelly Allison, who directs Penn's eating-disorders center, put it:
This research shows us that they might be useful to manage food preoccupation and binge eating, but not in their current form.
Penn Medicine, 2025.
We are about to spend a great deal of hope and money, only to learn slowly what the Vyvanse reviews already say. Silencing the food noise is not the same as keeping it silent, and a drug that works at the wrong hour does not work.
The strange part is that the repair may already exist, one specialty over. ADHD solved the evening problem long ago. A small afternoon booster dose, or a delayed-release stimulant taken at night that does not switch on until the next morning. None of it has been approved, or as far as I can tell even trialed, for binge eating.
That is the whole lesson, and the patients reached it first. The data we needed was sitting unread in public, in the reviews. People had already run the experiment on themselves and named the flaw. Some even sketched the repair. We keep crowning whatever turns the food noise off and calling it a cure, while the people who take these drugs are still asking the one question we have never built a drug around: and then what happens at night?
Common questions
What is binge eating disorder?
It is the most common eating disorder, marked by recurring episodes of eating unusually large amounts of food with a sense of being unable to stop, and without the compensating behaviors seen in bulimia. Vyvanse is the only medication the FDA has approved to treat it.
Is Vyvanse a weight-loss drug?
No. It is approved for binge eating disorder, not weight loss, and has not been evaluated as a weight-loss treatment. Some reviewers did lose weight and welcomed it, but others gained, and using it to slim down is off-label and not what the approval or the evidence supports.
Is Vyvanse addictive?
It is a stimulant and a controlled substance, so it carries real potential for misuse, and some reviewers worried about dependency. That history is why its 2015 approval for binge eating was controversial. Taken as prescribed, the reviews described tolerance, the drug doing less over time, more often than addiction, but it is a fair thing to raise with a clinician.
Contact
If this is the kind of work you care about,
I'd like to hear from you.